FATE Q3 2023 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-87.0% YoY

Gross Profit

-$3M-143.8% margin

Operating Income

-$51M-2637.8% margin

Net Income

-$45M-2323.6% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

+108.4%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$39M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$544M

Total Liabilities

$141M

Stockholders' Equity

$403M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$15M	-87.0%
Gross Profit	-$3M	-$65M	+95.7%
Operating Income	-$51M	-$86M	+40.6%
Net Income	-$45M	-$84M	+45.9%

Revenue Segments

Upfront Fee And Equity Premium

$31M100%